News feature: cellular cross-talk explains why pancreatic cancer resists chemotherapy
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies worldwide, with a five-year survival rate remaining in the single digits. Gemcitabine has long been a cornerstone of systemic therapy for PDAC, yet most patients eventually develop resistance, leading to disease progression and poor outcomes. Despite decades of clinical use, the biological mechanisms underlying gemcitabine resistance have remained incompletely understood.
In a new study, researchers combined cutting-edge transcriptomic technologies with experimental validation to reveal how interactions between specific tumor and immune cell populations drive chemotherapy resistance in pancreatic cancer. The work provides a comprehensive view of the cellular ecosystem that supports drug resistance and identifies new therapeutic vulnerabilities. The study was published in Chinese Medical Journal on December 26, 2025.
Mapping resistance at single-cell resolution
To dissect the complexity of gemcitabine resistance, the research team integrated bulk RNA sequencing, single-cell RNA sequencing, and spatial transcriptomics from pancreatic cancer samples. This multi-layered approach allowed them to not only identify resistance-associated gene programs, but also pinpoint the exact cell types and spatial contexts in which these programs operate.
The analysis revealed two cell populations that were consistently enriched in gemcitabine-resistant tumors: PRRX2+ epithelial cancer cells and SPP1+ tumor-associated macrophages (TAMs). Importantly, these cells were not acting in isolation. Computational modeling of cell–cell communication showed strong bidirectional signaling between the two populations, suggesting a coordinated resistance program.
A TGF-β–driven resistance circuit
Further investigation identified the TGFB1/TGFBR2 signaling axis as the molecular bridge linking PRRX2+ epithelial cells (EC) and SPP1+ macrophages. PRRX2, a transcription factor known to regulate cell plasticity, emerged as a central driver of this process. In epithelial tumor cells, PRRX2 amplified TGF-β signaling, inducing epithelial–mesenchymal transition, a program associated with enhanced invasiveness and drug tolerance.
At the same time, PRRX2 promoted extracellular matrix remodeling through activation of genes such as FN1, reshaping the tumor microenvironment into a dense, immunosuppressive niche. This remodeled environment further supported the accumulation and activation of SPP1+ macrophages, which in turn reinforced resistance-promoting signals back to tumor cells.
Experimental and clinical validation
The researchers validated these findings using a combination of in vitro experiments and multicolor immunofluorescence analysis of patient samples. Suppressing PRRX2 expression in pancreatic cancer cell lines significantly reduced cell migration, supporting its functional role in tumor aggressiveness. In clinical cohorts, tumors with high levels of PRRX2+ epithelial cells and SPP1+ macrophages were associated with poorer prognosis, underscoring the clinical relevance of the identified axis.
Implications for treatment
Beyond mechanistic insight, the study points to potential therapeutic strategies. Drug sensitivity analyses suggested that tumors enriched for the PRRX2+ EC/SPP1+ TAM signature may respond to dasatinib, a multi-kinase inhibitor, as well as antibody–drug conjugates targeting epithelial markers such as TROP2, MUC1, and CEACAM5. These findings support the rationale for combination or precision therapies aimed at both tumor cells and their microenvironment.
A step toward precision therapy in PDAC
By revealing how specific epithelial and immune cell populations cooperate to drive gemcitabine resistance, this study advances understanding of pancreatic cancer biology and highlights the importance of tumor microenvironmental interactions. The results suggest that overcoming drug resistance in PDAC will require strategies that disrupt these cellular communication networks, rather than targeting tumor cells alone.
As pancreatic cancer continues to pose a major clinical challenge, insights from integrative, single-cell–based studies such as this offer new hope for designing more effective, personalized treatment approaches.
***
Reference
DOI: 10.1097/CM9.0000000000003966
About Professor Lijuan Huo from Shanxi Medical University
Dr. Lijuan Huo, MD, PhD, is a Chief Physician, Level II Professor, and doctoral supervisor, and a nationally recognized medical expert in Shanxi Province as well as a recipient of the State Council Special Allowance. She has held multiple leadership positions in national gastroenterology societies, including the Chinese Society of Digestive Diseases and the Chinese Medical Doctor Association, and served as an editorial board member of the Chinese Journal of Digestion. From 2014 to 2024, Dr Huo served as Director of the Shanxi Digestive Medicine Quality Control Center.
About Dr. Feng Li from Cancer Hospital Affiliated to Shanxi Medical University/Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences
Dr. Feng Li is a Director of Education and Research at Shanxi Cancer Hospital, with postdoctoral training, and serves as a Research Fellow and Master’s Supervisor. Recognized as a “Sanjin Elite” Young Outstanding Talent and an Academic and Technical Leader of Shanxi Province, Dr. Li holds youth committee positions in the Tumor Markers, Methylation, and Tumor Prevention and Health Care branches of the Chinese Anti-Cancer Association. Additional roles include multiple committee appointments within the Shanxi Anti-Cancer Association, service as a high-level evaluation expert for the Shanxi Provincial Department of Science and Technology, and reviewing editor responsibilities for journals including Cancer Translational Medicine .
About Dr. Wenhui Yang from Cancer Hospital Affiliated to Shanxi Medical University/Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences
Dr. Wenhui Yang is a Director of Gastroenterology and an Associate Chief Physician. She holds a PhD in Oncology from Peking Union Medical College/Cancer Hospital, Chinese Academy of Medical Sciences, and completed postdoctoral training in biology. Serving as a master’s thesis advisor, Dr Yang has been recognized as a “Young Expert in Professional Positions” by the Shanxi Provincial Communist Youth League, a “Sanjin Talent” Young Outstanding Professional in the health sector, and a Young Medical Science and Technology Talent of Shanxi Province. Her research output includes more than 30 publications, over 10 of which are SCI indexed.
Funding information
This was supported by the Science and Education Cultivation Fund of the National Cancer and Regional Medical Center of Shanxi Provincial Cancer Hospital (No. SD2023004), Shanxi Special Projects of the Central Government Guiding Local Science and Technology Development of China (No. YDZJSX2024B012), Wu Jieping Medical Foundation (No. 320.6750.2024-13-46), Fundamental Research Program of Shanxi Province (No. 202303021221240), 2024 Shanxi Province Traditional Chinese Medicine Research Projects (No. 2024ZYY2D024), Shanxi Provincial Physician Association Clinical Research Projects for Physicians (No. YSXH-QL2023XH001), and Shanxi Provincial Physician Association Clinical Research Projects for Physicians (No. YSXH-QL2024ZHZL003).
Chinese Medical Journal
Experimental study
Cells
Single-cell and spatial transcriptomics reveal the interaction between PRRX2-driven epithelial cells and SPP1+ macrophages in mediating gemcitabine resistance in pancreatic ductal adenocarcinoma
26-Dec-2025